Eli Lilly and Company announced plans to sell its monoclonal antibody manufacturing site in New Jersey as part of a strategic shift focusing on advanced biologics. The divestiture aligns with evolving pharmaceutical market demands for more complex therapies beyond traditional antibodies. Lilly is pursuing new U.S. manufacturing investments to enhance capabilities in innovative biologics, signaling a forward-looking operational realignment that supports pipeline development for next-generation therapeutics.